Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyramidal Cells | 12 | 2019 | 34 | 2.810 |
Why?
|
| Cocaine | 13 | 2015 | 31 | 2.590 |
Why?
|
| Prefrontal Cortex | 13 | 2019 | 103 | 2.570 |
Why?
|
| Calcium Channels, L-Type | 7 | 2017 | 52 | 2.340 |
Why?
|
| HIV-1 | 8 | 2019 | 203 | 1.790 |
Why?
|
| Nucleus Accumbens | 8 | 2011 | 12 | 1.780 |
Why?
|
| Neurons | 10 | 2017 | 273 | 1.600 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 5 | 2016 | 11 | 1.530 |
Why?
|
| Action Potentials | 9 | 2019 | 83 | 1.290 |
Why?
|
| AIDS Dementia Complex | 4 | 2017 | 39 | 1.140 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2011 | 12 | 1.010 |
Why?
|
| Rats | 20 | 2019 | 626 | 1.000 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2016 | 22 | 0.960 |
Why?
|
| Animals | 25 | 2023 | 3311 | 0.960 |
Why?
|
| Calcium | 6 | 2017 | 369 | 0.890 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2023 | 1 | 0.820 |
Why?
|
| Zinc | 1 | 2023 | 39 | 0.800 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2015 | 315 | 0.740 |
Why?
|
| Aging | 2 | 2019 | 1102 | 0.690 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2019 | 11 | 0.680 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2019 | 6 | 0.670 |
Why?
|
| Neuronal Plasticity | 4 | 2009 | 38 | 0.630 |
Why?
|
| HIV Infections | 3 | 2019 | 431 | 0.600 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2010 | 34 | 0.580 |
Why?
|
| Membrane Potentials | 8 | 2016 | 168 | 0.520 |
Why?
|
| Sodium Channels | 3 | 2006 | 13 | 0.510 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 125 | 0.480 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2006 | 10 | 0.470 |
Why?
|
| Potassium Channels | 2 | 2006 | 36 | 0.470 |
Why?
|
| Patch-Clamp Techniques | 9 | 2016 | 97 | 0.450 |
Why?
|
| Male | 21 | 2019 | 12466 | 0.440 |
Why?
|
| Substance-Related Disorders | 3 | 2017 | 87 | 0.440 |
Why?
|
| Calcium Channels | 4 | 2011 | 107 | 0.420 |
Why?
|
| Homeostasis | 2 | 2011 | 65 | 0.410 |
Why?
|
| Central Nervous System Stimulants | 3 | 2017 | 39 | 0.400 |
Why?
|
| In Vitro Techniques | 7 | 2011 | 153 | 0.360 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2011 | 6 | 0.360 |
Why?
|
| Signal Transduction | 6 | 2017 | 398 | 0.350 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 6 | 2011 | 35 | 0.340 |
Why?
|
| Calcineurin | 2 | 2011 | 8 | 0.320 |
Why?
|
| Calcium Signaling | 2 | 2016 | 119 | 0.310 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2011 | 6 | 0.290 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2006 | 2 | 0.250 |
Why?
|
| Cyclic AMP | 3 | 2005 | 31 | 0.250 |
Why?
|
| Enzyme Inhibitors | 6 | 2011 | 112 | 0.250 |
Why?
|
| Phosphoproteins | 1 | 2005 | 23 | 0.230 |
Why?
|
| Ion Channels | 1 | 2007 | 204 | 0.230 |
Why?
|
| Muscarine | 1 | 2004 | 2 | 0.220 |
Why?
|
| Methamphetamine | 2 | 2017 | 22 | 0.220 |
Why?
|
| Dopamine Agonists | 4 | 2011 | 15 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 128 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 315 | 0.210 |
Why?
|
| beta Catenin | 2 | 2017 | 57 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2023 | 4 | 0.210 |
Why?
|
| Ligands | 1 | 2023 | 37 | 0.200 |
Why?
|
| Caco-2 Cells | 1 | 2023 | 43 | 0.200 |
Why?
|
| Cytosol | 1 | 2023 | 41 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 526 | 0.200 |
Why?
|
| Ventral Tegmental Area | 1 | 2002 | 7 | 0.190 |
Why?
|
| Amphetamine | 1 | 2002 | 5 | 0.190 |
Why?
|
| Mice | 2 | 2023 | 1263 | 0.180 |
Why?
|
| Electric Stimulation | 4 | 2011 | 46 | 0.170 |
Why?
|
| Rats, Transgenic | 2 | 2017 | 17 | 0.170 |
Why?
|
| Time Factors | 5 | 2011 | 1262 | 0.160 |
Why?
|
| Humans | 7 | 2023 | 22958 | 0.160 |
Why?
|
| Dopamine | 3 | 2007 | 77 | 0.160 |
Why?
|
| Analysis of Variance | 2 | 2011 | 228 | 0.160 |
Why?
|
| Drug Interactions | 3 | 2011 | 35 | 0.160 |
Why?
|
| Dopamine Antagonists | 3 | 2011 | 5 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2011 | 153 | 0.140 |
Why?
|
| Self Administration | 2 | 2015 | 16 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2019 | 284 | 0.140 |
Why?
|
| Salicylamides | 2 | 2011 | 2 | 0.140 |
Why?
|
| Quinpirole | 2 | 2011 | 3 | 0.140 |
Why?
|
| Astrocytes | 2 | 2017 | 126 | 0.140 |
Why?
|
| Gene Expression | 1 | 2017 | 178 | 0.130 |
Why?
|
| Cortical Excitability | 1 | 2015 | 1 | 0.120 |
Why?
|
| Electrophysiological Phenomena | 1 | 2016 | 8 | 0.120 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 174 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 232 | 0.120 |
Why?
|
| Drug-Seeking Behavior | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cues | 1 | 2015 | 37 | 0.110 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 12 | 0.110 |
Why?
|
| Potassium Channel Blockers | 3 | 2009 | 5 | 0.100 |
Why?
|
| Motor Cortex | 2 | 2009 | 16 | 0.090 |
Why?
|
| Reward | 2 | 2010 | 18 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2010 | 5 | 0.080 |
Why?
|
| Sodium Channel Blockers | 2 | 2006 | 2 | 0.080 |
Why?
|
| Cross-Linking Reagents | 1 | 2009 | 10 | 0.080 |
Why?
|
| Protein Transport | 1 | 2009 | 29 | 0.080 |
Why?
|
| Synapses | 1 | 2009 | 23 | 0.080 |
Why?
|
| Brain | 1 | 2016 | 1203 | 0.070 |
Why?
|
| Calcium Channel Blockers | 2 | 2005 | 30 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2005 | 132 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 267 | 0.070 |
Why?
|
| Receptors, Dopamine | 1 | 2007 | 8 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 42 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 20 | 0.060 |
Why?
|
| Type C Phospholipases | 1 | 2006 | 8 | 0.060 |
Why?
|
| Protein Phosphatase 1 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Adenylyl Cyclases | 1 | 2005 | 10 | 0.060 |
Why?
|
| Muscarinic Antagonists | 1 | 2004 | 1 | 0.060 |
Why?
|
| Pertussis Toxin | 1 | 2004 | 3 | 0.060 |
Why?
|
| Atropine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Parasympathomimetics | 1 | 2004 | 4 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2004 | 4 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 131 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2004 | 11 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 2006 | 176 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2004 | 13 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2004 | 19 | 0.060 |
Why?
|
| Genes, Immediate-Early | 1 | 2002 | 1 | 0.050 |
Why?
|
| Microinjections | 1 | 2002 | 4 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 17 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2009 | 13 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2017 | 15 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 19 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 24 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 28 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 2015 | 3 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 33 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 228 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 336 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 132 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 89 | 0.020 |
Why?
|
| Indazoles | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 250 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2010 | 13 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2010 | 47 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 144 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 426 | 0.020 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2009 | 1 | 0.020 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2009 | 3 | 0.020 |
Why?
|
| Apamin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 7 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 19 | 0.020 |
Why?
|
| Macrolides | 1 | 2009 | 6 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 15 | 0.020 |
Why?
|
| Biophysics | 1 | 2009 | 32 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 36 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 47 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 76 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 89 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2009 | 152 | 0.020 |
Why?
|
| Kynurenic Acid | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cadmium Chloride | 1 | 2005 | 1 | 0.010 |
Why?
|
| Tetrodotoxin | 1 | 2005 | 2 | 0.010 |
Why?
|
| GABA Antagonists | 1 | 2005 | 2 | 0.010 |
Why?
|
| Tetraethylammonium | 1 | 2005 | 4 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 9 | 0.010 |
Why?
|
| Cesium | 1 | 2005 | 13 | 0.010 |
Why?
|
| Nifedipine | 1 | 2005 | 6 | 0.010 |
Why?
|
| Chlorides | 1 | 2005 | 25 | 0.010 |
Why?
|
| Barium | 1 | 2004 | 13 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cell Separation | 1 | 2004 | 21 | 0.010 |
Why?
|